Last reviewed · How we verify
Hyperglycemia
Hyperglycemia is a Small molecule drug developed by Mayo Clinic. It is currently in Phase 1 development.
Hyperglycemia is a medical condition characterized by an unusually high amount of glucose in the blood, defined as a blood glucose level exceeding 6.9 mmol/L after fasting for 8 hours or 10 mmol/L 2 hours after eating. It is associated with various conditions, including Type 1 and Type 2 Diabetes, and has been studied in clinical trials for potential treatments such as rosiglitazone/metformin.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Hyperglycemia |
|---|---|
| Sponsor | Mayo Clinic |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Evaluation of the Clinical Spectrum of Diabetes and Obesity in Youth and Adults
- Effects of Diabetic Educational Intervention and Dietary Supplements on Blood Glucose, Lipid Profile Levels, Body Mass Index, and Pain Management Among Adult Individuals With Painful Diabetic Peripheral Neuropathy. (NA)
- Blood Glucose Screening in Patients With Advanced Periodontits: the Role of Specialist Periodontal Care in Identifying Hyperglycaemia and Supporting Patient Centered Treatment
- Investigating the Use of Quercetin on Glucose Absorption in Obesity, and Obesity With Type 2 Diabetes (PHASE2)
- Shunt-dependency After aSAH - Role of Early Hyperglycaemia in CSF and Blood
- Effects of Vitamin D and Calcium on Hyperglycemia and Dyslipidemia in Patients Gestational Diabetes (NA)
- Understanding the Health Effect of a Bioactive Peptide From Egg: A Pilot Study (PHASE1)
- Isoleucine Addition Treatment Effects in a Controlled Diet Study (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hyperglycemia CI brief — competitive landscape report
- Hyperglycemia updates RSS · CI watch RSS
- Mayo Clinic portfolio CI
Frequently asked questions about Hyperglycemia
What is Hyperglycemia?
Who makes Hyperglycemia?
What development phase is Hyperglycemia in?
Related
- Manufacturer: Mayo Clinic — full pipeline
- Therapeutic area: All drugs in Metabolic
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing